Boston Scientific Announces Agreement to Acquire Axonics, Inc.

Boston Scientific Corporation

Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Axonics, Inc. (Nasdaq: AXNX), a publicly traded medical technology company primarily focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. The purchase price is $71 in cash per share, reflecting an equity value of approximately $3.7 billion and an enterprise value of approximately $3.4 billion.1


In the United States, it is estimated that nearly 30 million adults ages 40 and older have bothersome symptoms of overactive bladder (OAB) and 19 million adults have fecal incontinence.2,3 These conditions can have a significant impact on quality of life, mental health, sleep, productivity and social activities.4

SNM Therapy

The Axonics product portfolio includes the Axonics R20TM and the Axonics F15TM Systems used to deliver sacral neuromodulation (SNM) therapy. SNM therapy is a minimally invasive procedure used in the treatment of OAB and fecal incontinence. It works by delivering mild electrical pulses to the sacral nerve to restore communication between the brain and the bladder. In clinical studies, Axonics Therapy has demonstrated meaningful improvement in patients’ quality of life in follow-up out to two years, with no serious device-related adverse events reported.5,6

Meghan Scanlon, senior vice president and president, Urology, Boston Scientific Comments…

“We are excited to add Axonics technologies to the Boston Scientific portfolio, a combination that we expect will further strengthen our ability to serve urologists who are treating patients living with these often-chronic conditions”

She added, “This acquisition also enables our entry into sacral neuromodulation, a high-growth adjacency with opportunities to expand access to care for patients.”

Received FDA Approval January 2023

In January 2023, Axonics received U.S. Food and Drug Administration (FDA) approval for its fourth-generation Axonics R20 neurostimulator, a rechargeable SNM device with a battery life of 20 or more years. The company’s portfolio also includes Bulkamid® Urethral Bulking System for the treatment of female stress urinary incontinence.

Completion of Transaction

Boston Scientific expects to complete the transaction in the first half of 2024, subject to customary closing conditions. Axonics expects to deliver net revenue of approximately $366 million in 2023, representing 34% growth over the prior fiscal year.7 Axonics’ revenue growth profile is anticipated to be highly accretive to the Boston Scientific Urology business in 2024. The impact to Boston Scientific adjusted earnings per share is expected to be immaterial in 2024 and accretive thereafter. The impact to GAAP earnings per share is expected to be less accretive, or more dilutive, due to amortization expense and acquisition-related net charges.

Additional information about this transaction is available on the Events and Presentations section of the Boston Scientific investor relations website.

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

In addition, Wave Neuroscience has acquired the Neuro-EEG Synchronization Therapy (NEST®) system developed and tested by NeoSync.
E Tech Group announces the immediate renaming of E-Volve Systems to E Tech Group, following their strategic acquisition on February 23, 2023, emphasizing a unified vision, expanded services, and enhanced client and market value through this integration.
ClorDiSys is a family-owned and operated company that began in 2001 as a decontamination equipment provider but quickly added surface-top disinfection products, as well as on-site decontamination services to its portfolio to better address customer challenges
Based in El Paso, Texas, Seisa is a medical device manufacturer servicing every stage of the product life cycle including design and development, component manufacturing, and final assembly. It employs more than 2,000 people across four facilities in the U.S., Mexico and Slovakia.
SERF SAS is recognized by healthcare professionals worldwide for its innovations in hip implants, including the invention of the original Dual Mobility Cup.

By using this website you agree to accept Medical Device News Magazine Privacy Policy